Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency presents four regulatory options for the Endocrinologic and Metabolic Drugs Advisory Committee's Sept. 15 review of sibutramine's cardiovascular safety, ranging from continued marketing with no labeling changes to withdrawal.

You may also be interested in...



Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says

Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.

Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says

Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.

Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use

A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever

Related Content

Topics

UsernamePublicRestriction

Register

PS071161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel